Sydney, June 25, 2026, 04:04 AEST
- Cochlear ended the session at A$113.45, adding 0.59%. Shares climbed 6.17% for the week.
- Cochlear is sticking with its FY26 underlying profit outlook at A$290 million to A$330 million. That range was lowered in April from A$435 million-A$460 million.
- Cochlear is set to report full-year results on Aug. 18.
Cochlear traded up on Wednesday, staying above A$113. The stock stretched its rebound to a seventh session after April’s earnings cut from the hearing-implant company.
The stock finished the session at A$113.45, climbing 67 cents after moving between A$112.63 and A$115.13. Turnover hit 1.13 million shares, well above the recent daily average near 602,000. CSL added 2.63% and Pro Medicus rose 3.50% in Australian healthcare.
S&P/ASX 200 added 0.24% to close at 8,808.40. Tech and healthcare names did most of the work. Cochlear gained, but trailed the bigger moves in some large healthcare stocks.
ASX cash market was shut at the dateline, with regular trade set to reopen around 10 a.m. Sydney time.
Cochlear cut its FY26 underlying net profit outlook as weaker sales in developed markets and problems in the Middle East weighed on orders and deliveries. The company is guiding to second-half sales growth between 2% and 6% in constant currency, stripping out FX impacts. CEO Dig Howitt said, “We remain confident of our market leadership,” and pointed to strong adoption of the Nucleus Nexa system.
Cochlear said demand from emerging markets was still strong, but flagged cancelled and delayed orders in the Middle East and weaker premium sales in China. Third-quarter services revenue climbed 13% on the year. Acoustics revenue went up 11% in constant currency.
Sales revenue for the first half was up 1% at A$1.176 billion. Underlying net profit dropped 9% to A$194.8 million. Statutory profit slid 21%, coming in at A$161.5 million. The interim dividend was held at A$2.15 a share.
UBS trimmed its FY26 and FY27 earnings forecasts by 2%-3% on June 16, dropping its price target to A$106 from A$109 and sticking with a Neutral rating. UBS pointed to Middle East exposure and weaker U.S. referral checks, but said some sales just look delayed, not lost.
Jarden’s Steve Wheen and Tristan Maher said April’s downgrade was “far worse than anticipated” and warned that Cochlear’s repeated forecasting misses could threaten its valuation multiple. The Australian
The turnaround might not hold if profit comes in at the low end, U.S. referrals keep lagging, Middle East orders get pulled, or the Australian dollar stays high. Cochlear put possible receivables provisions at up to A$10 million and sees about A$20 million hit from lower gross margin, A$18 million to A$25 million from changes to the cost base, and around A$25 million from currency in the second half.
